Amphastar Pharmaceuticals, Inc. Co Selected Measure Amt
Amphastar Pharmaceuticals, Inc. (AMPH) reported Co Selected Measure Amt of -$1.7 for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-13.
Financial Statements › Notes
ecd:CoSelectedMeasureAmt · last filed 2026-04-13
| Period end | Co Selected Measure Amt 12 month |
|---|---|
| 2025-12-31 | -$1.70 DEF 14A · filed 2026-04-13 |
| 2024-12-31 | $13.60 DEF 14A · filed 2026-04-13 |
| 2023-12-31 | $29.10 DEF 14A · filed 2026-04-13 |
| 2022-12-31 | $14.00 DEF 14A · filed 2026-04-13 |
| 2021-12-31 | $25.10 DEF 14A · filed 2026-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |